N2VC34 logo

NovoCure BOVESPA:N2VC34 Stock Report

Last Price

R$18.67

Market Cap

R$20.6b

7D

0%

1Y

192.2%

Updated

23 Dec, 2024

Data

Company Financials +

N2VC34 Stock Overview

An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. More details

N2VC34 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

NovoCure Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for NovoCure
Historical stock prices
Current Share PriceUS$18.67
52 Week HighUS$20.24
52 Week LowUS$5.96
Beta0.76
1 Month Change94.28%
3 Month Change93.67%
1 Year Change192.18%
3 Year Changen/a
5 Year Changen/a
Change since IPO-54.64%

Recent News & Updates

Recent updates

Shareholder Returns

N2VC34BR Medical EquipmentBR Market
7D0%-1.4%-2.1%
1Y192.2%7.2%-11.7%

Return vs Industry: N2VC34 exceeded the BR Medical Equipment industry which returned 7.2% over the past year.

Return vs Market: N2VC34 exceeded the BR Market which returned -11.7% over the past year.

Price Volatility

Is N2VC34's price volatile compared to industry and market?
N2VC34 volatility
N2VC34 Average Weekly Movementn/a
Medical Equipment Industry Average Movement7.0%
Market Average Movement5.1%
10% most volatile stocks in BR Market9.5%
10% least volatile stocks in BR Market2.8%

Stable Share Price: N2VC34's share price has been volatile over the past 3 months compared to the BR market.

Volatility Over Time: Insufficient data to determine N2VC34's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20001,453Asaf Danzigerwww.novocure.com

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.

NovoCure Limited Fundamentals Summary

How do NovoCure's earnings and revenue compare to its market cap?
N2VC34 fundamental statistics
Market capR$20.63b
Earnings (TTM)-R$927.43m
Revenue (TTM)R$3.58b

5.7x

P/S Ratio

-22.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
N2VC34 income statement (TTM)
RevenueUS$577.74m
Cost of RevenueUS$135.47m
Gross ProfitUS$442.26m
Other ExpensesUS$592.05m
Earnings-US$149.78m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.38
Gross Margin76.55%
Net Profit Margin-25.93%
Debt/Equity Ratio181.4%

How did N2VC34 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 01:06
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NovoCure Limited is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangAegis Capital Corporation
Gregory GilbertDeutsche Bank
Vijay KumarEvercore ISI